| http://www.w3.org/ns/prov#value | - Conclusion: This study confirmed the activity of the carboplatin/pemetrexed combination in the first-line treatment of patients with MPM. It is a viable option, especially in cases in which side effects are generally anticipated.Src inhibitors in lung cancer: Current status and future directionsVolume 11, Issue 4, July 2010, Pages 238-242Sacha I. Rothschild | Oliver Gautschi | Eric B. Haura | Faye
|
